Changes to the health care system enacted as part of health care reform in the U.S., as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private payors, could result in further pricing pressures. For example, initiatives by the U.S. government to impose most favored-nation pricing on U.S. prescription drug prices in government programs, including the recently proposed GUARD Model by the CMS.
